依维莫司
医学
细胞凋亡
慢性移植物肾病
糖尿病肾病
移植
泌尿科
药理学
肿瘤科
肾移植
内科学
肾
生物
生物化学
作者
Jens Lutz,Hequn Zou,Shanying Liu,Balázs Antus,Uwe W. Heemann
出处
期刊:Transplantation
[Wolters Kluwer]
日期:2003-08-15
卷期号:76 (3): 508-515
被引量:51
标识
DOI:10.1097/01.tp.0000074722.79186.a9
摘要
BACKGROUND: Chronic allograft nephropathy (CAN) is responsible for most cases of late kidney allograft loss. However, no effective treatment is available so far. Everolimus (RAD) (40-O [2-hydroxyethyl] rapamycin) is a new immunosuppressive agent with antiproliferative and apoptosis-enhancing effects. We asked whether everolimus can ameliorate CAN even at advanced stages, whether everolimus treatment affects the level of growth factor mRNA, and whether everolimus treatment affects the number of apoptotic cells in the graft. METHODS: We transplanted kidneys from Fisher rats into Lewis rats and treated recipients with everolimus over different time periods. Grafts were analyzed 20 or 28 weeks after transplantation. RESULTS: Everolimus delayed the progression of CAN when started at an early stage. Surprisingly, everolimus even ameliorated CAN when initiated at an advanced stage. Interestingly, apoptosis was more prevalent in treated animals, particularly in those with delayed treatment as compared with controls. CONCLUSIONS: Everolimus ameliorates CAN as a result of antiproliferative or apoptosis-enhancing effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI